Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice

Oncology Research

Volumn 11, Issue 6, 1999, Pages 273-280

  Ahmad, Imran ^a   Masters, Gregg R ^a   Schupsky, James J ^a   Nguyen, Josephine ^a   Ali, Shaukat ^a   Janoff, Andrew S ^a   Mayhew, Eric ^a  

^a Liposome Company Incorporated   (United States)

Author keywords

Cremophor ; EL; Human tumor models; Taxol ; Therapeutics; Toxicity; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL;

ANIMAL; ARTICLE; CELL SURVIVAL; DRUG SCREENING; FEMALE; HUMAN; MOUSE; MOUSE MUTANT; OVARY TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, SCID; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0033253860     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Clemons, M.; Leahy, M.; Valle, J.; Jayson, G.; Ranson, M.; Howell A. Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur. J. Cancer 33:2183-2193; 1997.
2. McGuire, W. P.; Rowinsky, E. K.; Rosenshein, N. B.; Grambine, F. C.; Ettinger, D. S.; Armstrong, D. K.; Donehower R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111:273-279; 1989.
3. Bunn, P. A., Jr. Defining the role of paclitaxel in lung cancer: Summary of recent studies and implications for future directions. Semin. Oncol. 24:153-162; 1997.
4. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93: 2325-2327; 1971.
5. Rowinsky, E. K.; Donehower R. C. Paclitaxel (Taxol®). N. Engl. J. Med. 332:1004-1014; 1995.
6. Rowinsky, E. K.; Cazenave, L. A.; Donehower, R. C. Taxol-a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82:1247-1259; 1990.
7. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667; 1979.
8. Burkhart, C. A.; Berman, J. W.; Swindell, C. S.; Horwitz, S. B. Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor-a gene expression and cytotoxicity. Cancer Res. 54:5779-5782; 1994.
9. Gibson, S.; Widman, C.; Johnson, G. L. Differential involvement of MEK kinase (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. J. Biol. Chem. 274:10916-10922; 1999.
10. Haldar, S.; Basu, A.; Croce, C. M. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 58:1609-1615; 1998.
11. Jun, C. D.; Choi, B. M.; Kim, H. M.; Chung, H. T. Involvement of protein kinase C during Taxol-induced activation of murine peritoneal macrophages. J. Immunol. 154:6541-6547; 1995.
12. Greenwald, R. B.; Gilbert, C. W.; Pcndri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: Water soluble Taxol 2'poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39:424-431; 1996.
13. Nicolaou, K. C.; Reimer, C; Kerr, M. A.; Rideout, D.; Wrasidlo, W. Design, synthesis, and activity of protaxols. Nature 364:464-466; 1993.
14. Ringel, I.; Horwitz, S. B. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J. Natl. Cancer Inst. 83:288-291; 1991.
15. Ahmad, I.; Ali, S.; Janoff, A. S.; Masters, G. R.; Nagy, M.; Pattassery, J. S.; Peters, A. C.; Schupsky, J. J.; Mayhew, E. Toxicity and anticancer activity of 2'-oc-bromo-hexadecanoyl paclitaxel against intraperitoneal human ovarian tumor xenograft in SCID mice. Proc. Am. Assoc. Cane. Res. 38:41; 1997.
16. Ahmad, I.; Masters, G. R.; Nagy, M.; Schupsky, J. J.; Ali, S.; Janoff, A. S.; Peters, A. C.; Mayhew, E. Anticancer activity of 2'-a-bromo-hexadecanoyl paclitaxel (2'Br-C16-HTD) and Taxol' against human and mouse tumors. Proc. Am. Assoc. Cane. Res. 39:10; 1998.
17. Gupta, C. M.; Radhakrishnan, R.; Khorana, H. G. Glycerophospholipid synthesis: Improved general method and new analogs containing photoactivable groups. Proc. Natl. Acad. Sci. USA 74: 4315-4319; 1977.
18. Sharma, A.; Mayhew, E.; Bolcsak, L.; Cavanaugh, C.; Hormon, P.; Janoff, A. S.; Bernacki, R. S. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 71:103-107; 1997.
19. Straubinger, R. M. Biopharmaceutics of paclitaxel (Taxol): Formulation, activity, and pharmacokinetics. In: Suffness, M., eds. Taxol5 science and applications. Boca Raton: CRC Press, Inc.; 1995:237-258.
20. Huang, S. K.; Mayhew, E.; Gilani, S.; Lasic, D. D.; Martin, F. J.; Papahadjopoulos, D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:6774-6781; 1992.
21. Li, C.; Yu, D. F.; Newman, R. A.; Cabrai, F.; Stephens, L. C.; Hunter, N.; Milas, L.; Wallace, S. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 58:2404-2409; 1998.